Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 09:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced...
November 04, 2025 09:00 ET | Source: Compass Therapeutics

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed...
October 30, 2025 09:00 ET | Source: Nouscom Srl

Nouscom to Present New Positive Phase 1b/2 Clinical and Translational Data on NOUS-209 Immunogenicity and Cancer Interception Potential in Lynch Syndrome Carriers at SITC 2025

Lynch Syndrome (LS) is a common hereditary condition that greatly increases lifetime risk of colorectal, endometrial, urothelial and other cancersNOUS-209 is an off-the-shelf immunotherapy...
October 27, 2025 10:10 ET | Source: SNS Insider pvt ltd

CAR T-Cell Therapies Market Size to Reach 34.42 billion by 2032 Growing at a CAGR of 26.0% - SNS Insider

Austin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- CAR T-Cell Therapies Market Size & Growth Analysis According to SNS Insider, the global CAR T-Cell Therapies Market was valued at USD 5.42 billion in...
October 20, 2025 09:15 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place...
October 13, 2025 16:20 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces $736,600 Private Placement

CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies...
September 25, 2025 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical...
September 22, 2025 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published a...
September 04, 2025 11:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI...
August 29, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...